Vonvendi is now approved for routine prophylaxis to reduce bleeding frequency in adults with all types of VWD (Type 1, 2, and 3). The Food and Drug Administration (FDA) has expanded the approval of ...

Scientists at the RCSI University of Medicine and Health Sciences in Dublin, Ireland, have discovered a new role for the blood clotting protein, von Willebrand Factor (VWF), that could lead to the ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the U.S. Food & Drug Administration (FDA) approved VONVENDI® [von ...

Results showed the median ABR for all bleeds was reduced by 54.7%. The Food and Drug Administration (FDA) has approved Vonvendi ® (von Willebrand factor [recombinant]) for routine prophylaxis to ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Despite ...

− Approval Expands Use of VONVENDI to Include Routine Prophylaxis to Reduce the Frequency of Bleeding Episodes in Adults with Type 1 and 2 Von Willebrand Disease (VWD) and On-Demand and Perioperative ...

Vonvendi is a lab-made version of von Willebrand factor (VWF), a protein your body needs for blood to clot. Affecting more than 3 million people in the U.S, von Willebrand disease (VWD) is a common ...

New research by RCSI University of Medicine and Health Sciences published in the Blood Journal has revealed that the age at which individuals are tested for von Willebrand disease (VWD), a common ...

Anti-epidermal growth factor (EGFR) antibody cetuximab in patients with stage IV colorectal carcinoma who failed all standard therapy: An Access Protocol No significant financial relationships to ...

Von Willebrand disease in dogs is the most common inherited blood disorder our canine friends suffer with, and it also happens in humans and many other species. It’s a bleeding disorder – a failure of ...